Updated Oct 20, 2026
/Rams receiver Davante Adams out 6-10 weeks with hamstring rupture/CDW appoints former Deloitte chief Sam Balaji to board/Copper outperforms gold as AI and defense demand surge/RLI Corp. third-quarter net earnings fall to $81.0 million/Everest Group recasts Q2 2026 financial metrics in 8-K filing/Singapore Ag Stocks Fall After Minister Warns on Haze Responsibility/Rams receiver Davante Adams out 6-10 weeks with hamstring rupture/CDW appoints former Deloitte chief Sam Balaji to board/Copper outperforms gold as AI and defense demand surge/RLI Corp. third-quarter net earnings fall to $81.0 million/Everest Group recasts Q2 2026 financial metrics in 8-K filing/Singapore Ag Stocks Fall After Minister Warns on Haze Responsibility

Nixxy clears Phase IIb interim

Nixxy Inc. reported interim Phase IIb data showing a 32% response rate vs consensus 28%. Trial enrolled 184 patients.

By Corinne Ashford2 min readNIXXNIXXY
Share

Key takeaways

  • Nixxy Inc. reported interim Phase IIb data showing a 32% response rate.
  • The 32% response rate exceeded the consensus estimate of 28%.
  • The trial enrolled 184 patients.

Frequently asked

What response rate did Nixxy report in its Phase IIb interim data?

Nixxy reported a 32% response rate in its interim Phase IIb data.

How did Nixxy's response rate compare to expectations?

The 32% response rate came in above the consensus estimate of 28%.

How many patients were enrolled in the trial?

The trial enrolled 184 patients.